CO5241355A1 - Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis - Google Patents

Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis

Info

Publication number
CO5241355A1
CO5241355A1 CO00001261A CO00001261A CO5241355A1 CO 5241355 A1 CO5241355 A1 CO 5241355A1 CO 00001261 A CO00001261 A CO 00001261A CO 00001261 A CO00001261 A CO 00001261A CO 5241355 A1 CO5241355 A1 CO 5241355A1
Authority
CO
Colombia
Prior art keywords
active
packaged form
hepatitis
nucleosidic
against hepatitis
Prior art date
Application number
CO00001261A
Other languages
English (en)
Inventor
Gillian Frances Atkinson
Ronald James Boon
G Vandepapelie Pierre
Anne Cecile Wettendorf Martine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5241355A1 publication Critical patent/CO5241355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forma envasada para una composición farmacéutica que comprende como ingredientes activos: (1) un agente antiviral activo contra el virus de la hepatitis B (2) una vacuna para profilaxis y tratamiento de la hepatitis B, dichos ingredientes de uso simultáneo o secuencial. 1Forma envasada para composición farmacéutica para el tratamiento de pacientes con virus de hepatitis B, dicha composición siendo administrada en forma simultánea o secuencial en cualquier orden de un agente antiviral activo contra el virus de hepatitis B y una vacuna contra la hepatitis B, dichos ingredientes en cantidad segura y eficaz.
CO00001261A 1999-01-12 2000-01-12 Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis CO5241355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12

Publications (1)

Publication Number Publication Date
CO5241355A1 true CO5241355A1 (es) 2003-01-31

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00001261A CO5241355A1 (es) 1999-01-12 2000-01-12 Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis

Country Status (19)

Country Link
EP (1) EP1140163A2 (es)
JP (1) JP2002534438A (es)
KR (1) KR20010090011A (es)
CN (1) CN1391482A (es)
AR (1) AR022250A1 (es)
AU (1) AU760574B2 (es)
BR (1) BR9916893A (es)
CA (1) CA2359110A1 (es)
CO (1) CO5241355A1 (es)
CZ (1) CZ20012544A3 (es)
HK (1) HK1041434A1 (es)
HU (1) HUP0105070A2 (es)
IL (1) IL144186A0 (es)
NO (1) NO20013337L (es)
NZ (1) NZ512890A (es)
PL (1) PL349347A1 (es)
TR (1) TR200102024T2 (es)
WO (1) WO2000041463A2 (es)
ZA (1) ZA200105690B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
WO2020134682A1 (zh) * 2018-12-24 2020-07-02 南京远大赛威信生物医药有限公司 用于治疗乙型肝炎的药物制剂及其制备方法和用途
US20240207395A1 (en) * 2021-04-07 2024-06-27 Denka Company Limited Adjuvant activity enhancer and adjuvant composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69031556T2 (de) * 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigene sowie Verfahren zu deren Herstellung
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen

Also Published As

Publication number Publication date
PL349347A1 (en) 2002-07-15
IL144186A0 (en) 2002-05-23
CN1391482A (zh) 2003-01-15
AU760574B2 (en) 2003-05-15
NZ512890A (en) 2003-09-26
HK1041434A1 (zh) 2002-07-12
ZA200105690B (en) 2002-09-25
TR200102024T2 (tr) 2001-12-21
BR9916893A (pt) 2001-11-20
AR022250A1 (es) 2002-09-04
CZ20012544A3 (cs) 2002-01-16
EP1140163A2 (en) 2001-10-10
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (en) 2000-07-20
CA2359110A1 (en) 2000-07-20
WO2000041463A3 (en) 2000-11-09
AU2100900A (en) 2000-08-01
KR20010090011A (ko) 2001-10-17
JP2002534438A (ja) 2002-10-15
HUP0105070A2 (hu) 2002-04-29
NO20013337L (no) 2001-08-17

Similar Documents

Publication Publication Date Title
AR029655A1 (es) Mejoras en formulaciones en pasta
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR033688A1 (es) Composicion parenteral reconstituible
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
CA2385755A1 (en) Prevention of colorectal cancer
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
ECSP003685A (es) Formulaciones orales de liberacion controlada
AR027287A1 (es) Gonadotrofina
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas

Legal Events

Date Code Title Description
FC Application refused